Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01721694
Other study ID # AZILOT-12
Secondary ID 131.835
Status Withdrawn
Phase Phase 3
First received November 2, 2012
Last updated December 10, 2014
Start date December 2012
Est. completion date May 2013

Study information

Verified date December 2014
Source Adapt Produtos Oftalmológicos Ltda.
Contact n/a
Is FDA regulated No
Health authority Brazil: National Health Surveillance Agency
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or conjunctivitis compared with the individual administration of azithromycin 1.5% and 0.5% Loteprednol (separately).


Description:

Estimated to be admitted a total of approximately 60 patients showing blepharitis and / or keratitis and / or conjunctivitis: 30 patients will be assigned to the group of Azithromycin 1.5%/Loteprednol 0.5% Eye Drops (fixed combination) + placebo and 30 patients will be assigned to the group of Azithromycin 1.5% + 0.5% Loteprednol (separately)


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients were male or female, of any race and age minimum of 18 years.

- Blepharitis should provide diagnostic and / or keratitis and / or conjunctivitis with or without bacterial involvement corneal by biomicroscopy, with positive staining corneal fluorescein and also provide a composite score = 2 on: bulbar conjunctival hyperemia, eyelid conjunctiva, secretion / exudate conjunctival erythema and flaking eyelids / eyelid crust on at least one eye (the same eye) on Day 1 visit

Exclusion Criteria:

- Intraocular hypertension or uncontrolled glaucoma.

- Use of contact lenses during the study.

- Capacity unilateral visual only.

- Suspected fungal infection, viral (eg, herpes simplex epithelial, dendritic keratitis) or Acanthamoeba, or any other disease where the use of corticosteroids is contraindicated.

- Use of any topical ophthalmic medications preserved during study participation. Not be allowed eyedrops preserved (eg artificial tears).

- Use of any antibacterial agent oral or topical ophthalmic until 72 hours prior to study entry.

- Use of systemic steroids within 14 days prior to study entry. Ophthalmic topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs), until one week before admission to the study. Will not be allowed to use these medications during study participation. Will not be allowed to use nasal steroids during the study. Will be allowed to use inhaled steroids to aid inhaler. Will be allowed steroids dermal topics.

- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) systemic up to 24 hours prior to study entry or at any time during the study, unless the patient is under treatment regimen with stable (not necessary) for at least 2 months before Admission and therapy continues throughout the study.

- Any disturbance or ocular or systemic disease, complicating factors or structural abnormality that affects the conduct or outcome of the study in a negative way or represents an undue risk to patient safety, according to the opinion of the investigator.

- Any current immunosuppressive disorder (eg, HIV-positive), or immunosuppressive therapy (including chemotherapy).

- Known allergy or suspected allergy or hypersensitivity to fluoroquinolones, to steroids or any other component of the study drug;

- Pregnant or lactating. (Women of childbearing age may be admitted if they use contraception and submit urine pregnancy test negative);

- Any patient who has a family member who participates in this study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
azithromycin 1.5%/Loteprednol 0,5% + placebo
1 drop, AO, QID
azithromycin 1.5% + Loteprednol 0,5% (separately)
1 drop, QID, AO

Locations

Country Name City State
Brazil Department of Ophthalmology of Hospital São Paulo São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Adapt Produtos Oftalmológicos Ltda.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other ophthalmic evaluation decrease of visual acuity, corneal/anterior chamber changes, IOP increase and adverse event reporting Day 4 and Day 8 Yes
Primary Clinical cure Clinical cure achieved when the score of the cardinal ocular signs (hyperemia in the bulbar conjunctiva, palpebral, exudate / conjunctival discharge, eyelid erythema and flaking / crust eyelid) is zero at the time of conclusion of the study (D8) Day 8 No
Secondary irradication of pathogens Success obtained with microbiological irradication of pathogens present at baseline Day 8 No
See also
  Status Clinical Trial Phase
Completed NCT00513734 - A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill N/A
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Completed NCT01268306 - Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses Phase 4
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Completed NCT04169061 - Impact of Acthar on Everyday Life of Participants With Severe Keratitis Phase 4
Completed NCT03237936 - Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis Phase 4
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Terminated NCT05250583 - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis Phase 2
Recruiting NCT02865876 - Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis Phase 3
Terminated NCT02116062 - Robotic Surgery of the Ocular Surface N/A
Recruiting NCT00838422 - Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound N/A
Completed NCT00949468 - Microbiological Keratitis in a Countryside City of Brazil N/A
Completed NCT03586505 - Tolerance to Light for Patients Suffering From Keratitis N/A
Recruiting NCT04420962 - Automated Quantitative Ulcer Analysis Study
Completed NCT02186431 - Contact Lenses and Infiltrative Keratitis N/A
Completed NCT05538793 - Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study